view shopping cartrequest a quote
SearchLoginRegister
About Us
Products
Customer Support
Technical Support
Literature
News & Events

Home



 CIL History  Facilities  CIL Team  Distributors  Careers  Grant Programs/Scholarships

 Business of CIL  Milestones


Milestones


1981  
 
  • Business founded by Joel C. Bradley, Ph.D., MIT, to provide isotopically labeled research compounds and NMR solvents to the new and developing commercial market for stable isotope labeled compounds.
1983  
 
  • Moved from Cambridge, Massachusetts to larger laboratory space in Woburn, Massachusetts to accommodate the expanding staff and laboratories.
  • Provided PCB and PCDF standards in response to transformer fires in Binghamton, NY and San Francisco, CA which emitted PCBs and PCDFs into the atmosphere.
1985  
 
  • Established international presence with first major Sales Representative in Europe.
  • Developed standards for EPA assessment of the contamination at Times Beach, MO which was the “largest civilian exposure to dioxin in the US”
1986  
 
  • Founded CIL Japan and established offices in Osaka and Tokyo.
1987  
 
  • Raised expansion capital in an initial public offering on the Securities market in the United Kingdom.
  • Construction begins on $3.2 million 13C separation facility in Xenia, Ohio, the largest facility of its kind at the time.
  • Supplied standards for epidemiological study of long term affects of dioxins found in Agent Orange.
1988  
 
  • Acquired the stable isotope division of ICN Biomedicals, a competitor in stable isotope research products.
  • Established the first field sales force in the industry in the United States.
1990  
 
  • Invested in the first super conducting FT/NMR spectrometer to match the quality assurance capabilities of our best customers.
1992  
 
  • Achieved $10 Million in sales.
  • Purchased a second super conducting FT/NMR spectrometer.
  • First produced 13C PAH standards
1993  
 
  • Acquired the assets of MSD Isotopes from Merck Frost of Canada, a major competitor and the oldest stable isotope company in the industry.
  • Awarded $100,000 in 13C products in the first CIL Research Grant Program to promote novel applications of 13C by the research community.
1994  
 
  • Built state-of-the-art laboratories at our new site in Andover, Massachusetts to bring all laboratory operations under one roof and to provide space for expansion.
  • Implemented GMP programs.
  • Established biochemical synthesis facility in Canada
  • Introduced 1st generation of cell growth media
  • 18O first produced
1995  
 
  • Awarded over $100,000 in 13C & D compounds in a second CIL Research Grant Program.
  • 13C Urea manufactured to cGMP
  • CIL catalog introduced as evidence in the OJ Simpson
    “Trial of the Century”
1996  
 
  • Significant expansion of production capacity of 13C separation facility in Ohio to meet the growing demand, again the largest facility of its kind at the time.
1997

 

 
  • Development of BioExpress, 2nd generation cell growth media
1998  
 
  • Corporate merger with Otsuka Pharmaceuticals to facilitate a joint development of certain medical diagnostic products. CIL continues operations with the same executives and key managers and with an independent Board of Directors.
  • Former Senator John Glenn, infused with CIL amino acids
    for tracer studies during shuttle mission
  • Developed 13C PBDE standards
1999  
 
  • Construction begins on $6 Million 18O separation facility in Xenia, Ohio to meet the rapidly expanding needs of the Positron Emission Tomography (PET) and the metabolism research markets, again the largest in the world.
  • Synthesized 13C labeled cyclodiene pestides for CDC/ NHANES exploring human pesticide exposure in families of agricultural workers.
2001  
 
  • Completed construction on 18O separation facility.
  • Established close partnership with Euriso-top S.A
2000  
 
  • Exceeded $25 million in sales
2001  
 
  • First expansion of 18O separation facility production completed
  • Acquired Euriso-top S.A., largest stable isotope company in Europe
2002  
 
  • Acquired Tracer Technologies inventory of metabolic substrates
2003  
 
  • Completed 2nd expansion of 18O separation facility increasing production capacity to 250kg becoming world’s largest producer of 18O
  • Collaboration established with P.S.F. (Protein Structure Factory)
  • CIL and Cerilliant collaborate on chemical weapon
    standards for Homeland Security after 9/11
2004  
 
  • Exceed $45 million in sales
  • Introduced Insect Cell Growth Media
  • Collaboration established with Silantes, for RNA/DNA products
  • Provided dioxin standards for the forensic analysis on the poisoning of Victor Yushchenko
2005
  • Completed 15,000 sq ft expansion of QC, Production, and GMP laboratories
  • Established Otsuka Japanese based sales group
  • Increased cGMP API manufacturing
2006  
 
  • Cambridge Isotope Laboratories (Cil) Acquires Nuclear Medicine Chemical Manufacturer Abx Advanced Biochemical Compounds (Abx)
  • Introduced Mammalian Cell Growth Media
  • Became sponsors of triennial ISMAR prize
  • Collaboration established with Cassia, LLC founded by Dr. Jamie Williamson, for RNA/DNA products
  • Began distribution of NMR tubes for Norell
2007  
 
  • Cambridge Isotope Laboratories, Inc. Acquires M-fold Biotech GmbH
2008  
 
  • Cambridge Isotope Laboratories, Inc. (CIL) Announces Collaborative Venture with Membrane Receptor Technologies, LLC (MRT)
  • Cambridge Isotope Laboratories (CIL) and Cell Free Sciences (CFS) Announce Distribution Agreement
  • Cambridge Isotope Laboratories (Cil) Acquires Spectra Stable Isotopes (Ssi)
2010  
 
  • Developed Environmental Standard for the Gulf Oil Crisis
   
   

 

 


Request a Quote

go

50 Frontage Road
Andover, MA
01810-5413 USA
PH: 978.749.8000
PH: 800.322.1174
FAX:978.749.2768


All prices are in U.S. dollars for North American customers. All international customers should contact their local independent sales representatives or CIL International sales.